Quick Answer
BeOne Medicines Ltd. reported Research And Development Expense of $2.15 billion for the year ending 2025.
- BeOne Medicines Ltd. showed an increase of +9.9% in Research And Development Expense from 2024 to 2025.
- This data is from BeOne Medicines Ltd.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2014 to 2025 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 12 years of available data (2014 to 2025), BeOne Medicines Ltd.'s Research And Development Expense has grown by 9,715.5%.
- Historical annual values: Fiscal year 2025: $2.15 billion | Fiscal year 2024: $1.95 billion | Fiscal year 2023: $1.78 billion | Fiscal year 2022: $1.64 billion | Fiscal year 2021: $1.46 billion | Fiscal year 2020: $1.29 billion | Fiscal year 2019: $927.34 million | Fiscal year 2018: $679.01 million | Fiscal year 2017: $269.02 million | Fiscal year 2016: $98.03 million | Fiscal year 2015: $58.25 million | Fiscal year 2014: $21.86 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: